Item 2.02   Results of Operations and Financial Condition.
On August 5, 2021, Salarius Pharmaceuticals, Inc. (the "Company") reported
financial results for the three and six months ended June 30, 2021 and other
recent corporate updates. A copy of the press release is furnished as Exhibit
99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 of this Current Report on 8-K (including
Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the
liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of
1933, as amended. The information shall not be deemed incorporated by reference
into any other filing with the Securities and Exchange Commission made by the
Company, whether made before or after today's date, regardless of any general
incorporation language in such filing, except as shall be expressly set forth by
specific references in such filing.
Item 9.01 Financial Statements and Exhibits.
(d)  Exhibits
     Exhibit No.      Description
        99.1            Press Release Announcing Financial Results, dated August 5, 2021

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses